AA
REGN icon

Altman Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Altman Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,680
Closed -$306 – 88
2018
Q2 		$306 Buy
+5,680
New +$1.78M 0.28% 57

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Altman Advisors's REGN Position: Q3 2018 in Review

Altman Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 5,680 shares — an estimated $306 sold.

Altman Advisors first reported a position in REGN in Q2 2018 and held it in 1 quarter. The position peaked at $306 in Q2 2018. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

  • Altman Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Altman Advisors sold 5,680 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $306.
  • Altman Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Altman Advisors's Regeneron Pharmaceuticals position peaked at $306 in Q2 2018.
  • 644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Altman Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.